SCHEMBL207671

SCHEMBL207671

CS(=O)(=O)c1ccccc1-c1cc[c]cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.44
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD11B1 P28845 1/20 0.41
ALOX5AP P20292 2/20 0.39
FEN1 P39748 2/20 0.39
BAZ2B Q9UIF8 2/20 0.39
BAZ2A Q9UIF9 2/20 0.39
BRD9 Q9H8M2 1/20 0.39
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.38
ACLY P53396 1/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 1/20 0.37
MAOA P21397 1/20 0.36
LOX P28300 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415408 0.84 PTGS2 (0.61) PTGS2RAB9AKDM4EALDH1A1HSD11B1
SCHEMBL937206 0.84 PTGS2 (0.61) PTGS2RAB9AKDM4EALDH1A1HSD11B1
Hydrochloric Acid SCHEMBL7352630 0.82 PTGS2 (0.59) PTGS2RAB9AKDM4EALDH1A1HSD11B1
SCHEMBL7443147 0.81 PGAM1 (0.38) PTGS2HSD11B1KMT2AMEN1
SCHEMBL208435 0.81 CA1 (0.45) PTGS2ALOX5APFEN1
SCHEMBL15703721 0.80 PTGS2 (0.41) PTGS2RAB9AKDM4EALDH1A1HSD11B1
SCHEMBL7179157 0.80 FEN1 (0.45) ALOX5APFEN1
SCHEMBL8658514 0.80 PTGS2 (0.62) PTGS2RAB9AKDM4EALDH1A1HSD11B1
SCHEMBL7265178 0.78 PTGS2 (0.50) PTGS2RAB9AKDM4EALDH1A1HSD11B1
SCHEMBL5240256 0.78 PTGS2 (0.46) PTGS2KDM4EALDH1A1KMT2AACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP claimed
US-20030199698-A1 Carbamic acid esters as inhibitors of factor xa MERCK PATENT GMBH (DE) 2003-10-23 US claimed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US claimed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP claimed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO claimed
US-6090841-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS MERCK & CO., INC. (US) 2000-07-18 US claimed
EP-1925611-B1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO CO LTD (JP) 2016-04-13 EP disclosed
CN-103214414-B The diamine derivative of opticity and manufacture method thereof SANKYO CO. (JP) 2016-02-17 CN disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
US-20030199698-A1 Carbamic acid esters as inhibitors of factor xa MERCK PATENT GMBH (DE) 2003-10-23 US disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed
WO-1999026922-A1 SUBSTITUTED PYRROLE DERIVATIVES AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL PTGS2 2146/4885RAB9A 1817/4885KDM4E 4615/4885
US-20030199698-A1 Carbamic acid esters as inhibitors of factor xa F11, F12, F13A1 PTGS2 2473/4885RAB9A 932/4885KDM4E 1840/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 PTGS2 1584/4885RAB9A 2734/4885KDM4E 588/4885
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI PTGS2 1847/4885RAB9A 2909/4885KDM4E 2473/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R PTGS2 1692/4885RAB9A 3496/4885KDM4E 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.